A Prospective, Multicentric, Non-comparative Phase IV Clinical Trial Evaluating Safety and Efficacy of Fixed Dose Combination (FDC) of DICLOFENAC POTASSIUM BP + PARACETAMOL IP +TRYPSIN AND CHYMOTRYPSIN (50MG-+325MG+50,000 ARMOUR) FILM COATED TABLETS in the management of acute musculoskeletal pain

Aglowmed Pharma0 个研究点目标入组 200 人开始时间: 待定最近更新: 2022年10月17日

试验速览

暂无简介。

•1)Male or female patients between 20-65 years of age,
•2)Willing to give written informed consent and willing to comply with trial protocol.
•3)Out patients with diagnosis of acute musculoskeletal pain.
•4) Patients with at least 6 mm baseline pain rating on VAS scale.
•5)Patients not on any anti-inflammatory or other therapy in the past 2 weeks known to affect the study outcome.
•6)Ready to comply with protocol.
•7)Patients with normal renal and hepatic function as assessed by laboratory examination

•1) Pregnant and lactating women
•2) Patients with H/O any drug allergy
•3) Unwilling to comply with the protocol requirements
•4) Patients with gastro-intestinal disease, peptic ulcer, bleeding disorder and fecal blood loss.
•5) Patients with cardiac, hepatic, renal dysfunction and haemopoetic disorder
•6) Patients with hypertension
•7) Patients deemed ineligible by the investigator
•8) H/O skin lesions, skin ulcers

发起方

Aglowmed Pharma